Efficacy, safety and implementation outcomes of Cabotegravir plus Rilpivirine long-acting by country in the Cabotegravir and rilpivirine implementation study in European locations (CARISEL)

被引：0
|
作者：
Jonsson-Oldenbuettel, C. [1 ,2 ]
Ghosn, J. [3 ,4 ]
Sierra, J. Olalla [5 ]
van der Valk, M. [6 ]
Lutz, T. [7 ]
Belkhir, L. [8 ]
van Welzen, B. J. [9 ]
Hove, K. [10 ]
Ait-Khaled, M. [10 ]
DeMoor, R. [11 ]
Bontempo, G. [12 ]
Latham, C. L. [12 ]
Ngenzi, B. [13 ]
Okoli, C. [10 ]
Gutner, C. A. [12 ]
Iyer, S. [14 ]
Gill, M. [15 ]
Czarnogorski, M. [12 ]
D'Amico, R. [12 ]
van Wyk, J. [10 ]
机构：
[1] MVZ Munchen Goethepl, Munich, Germany
[2] MUC Res GmbH, Munich, Germany
[3] Univ Paris, INSERM, UMR 1137, IAME, Paris, France
[4] Hop Bichat Claude Bernard, Serv Malad Infect & Tropicales, AP HP, Paris, France
[5] Costa Sol Hosp, Dept Internal Med, Marbella, Spain
[6] Univ Amsterdam, Amsterdam Inst Infect & Immun, Dept Infect Dis, Amsterdam, Netherlands
[7] Infektio Res, Frankfurt, Germany
[8] Clin Univ St Luc, Brussels, Belgium
[9] Univ Med Ctr Utrecht, Utrecht, Netherlands
[10] ViiV Healthcare, Brentford, England
[11] GSK, Collegeville, PA USA
[12] ViiV Healthcare, Durham, NC USA
[13] ViiV Healthcare, Wavre, Belgium
[14] GSK, Bangalore, Karnataka, India
[15] GSK, Brentford, England
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
EACS2023:
引用
收藏
页码：193 / 195
页数：3
相关论文
共 50 条
  • [41] WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS
    Patel, P.
    D'Amico, R.
    Thiagarajah, S.
    Wu, S.
    Elliot, E.
    Polli, J. W.
    Upadhyay, O.
    Van Solingen-Ristea, R.
    Orkin, C.
    Overton, E. T.
    Swindells, S.
    van Wyk, J.
    Bosse, M.
    Vannappagari, V.
    Gray, L.
    [J]. SEXUAL HEALTH, 2021, 18 (04) : VI - VI
  • [42] Uptake and discontinuation of the long-acting duo in the Swiss HIV Cohort Study: Preliminary analysis on cabotegravir plus rilpivirine
    Ramirez, J. J. Duran
    Kusejko, K.
    Metzner, K. J.
    Huber, M.
    Martin, Y.
    Stockle, M.
    Calmy, A.
    Decosterd, L. A.
    Cavassini, M.
    Bernasconi, E.
    Schmid, P.
    Gunthard, H. F.
    Braun, D. L.
    [J]. HIV MEDICINE, 2023, 24 : 79 - 81
  • [43] Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People With HIV Who Are Virally Unsuppressed
    Hickey, Matthew D.
    Grochowski, Janet
    Mayorga-Munoz, Francis
    Oskarsson, Jon
    Imbert, Elizabeth
    Spinelli, Matthew
    Szumowski, John D.
    Appa, Ayesha
    Koester, Kimberly
    Dauria, Emily F.
    Mcnulty, Moira
    Colasanti, Jonathan
    Havlir, Diane V.
    Gandhi, Monica
    Christopoulos, Katerina A.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (03) : 280 - 289
  • [44] Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice
    Borghetti, Alberto
    Farinacci, Damiano
    Ciccullo, Arturo
    Dusina, Alex
    Moschese, Davide
    Iannone, Valentina
    D'Angelillo, Anna
    Lombardi, Francesca
    Delle Donne, Valentina
    Massaroni, Valentina
    Visconti, Elena
    Tamburrini, Enrica
    Di Giambenedetto, Simona
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (10) : 4970 - 4974
  • [45] Safety of cabotegravir/rilpivirine long acting for individuals previously exposed to HBV infection
    Bana, N. B.
    Rezzonico, L. F.
    Peracchi, F.
    Raimondi, A.
    Moioli, C.
    Chianura, L.
    Puoti, M.
    Rossotti, R.
    [J]. HIV MEDICINE, 2023, 24 : 131 - 133
  • [46] Cabotegravir plus rilpivirine as long-acting maintenance therapy: LATTE-2 week 48 results
    Margolis, D.
    Podzamczer, D.
    Stellbrink, H-J
    Lutz, T.
    Angel, J.
    Richmond, G.
    Clotet, B.
    Gutierrez, F.
    Sloan, L.
    Griffith, S.
    St Clair, M.
    Dorey, D.
    Ford, S.
    Mrus, J.
    Crauwels, H.
    Smith, K.
    Williams, P.
    Spreen, W.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [47] Safety and efficacy of cabotegravir plus rilpivirine long acting with and without oral lead-in: FLAIR week 124 results
    D'Amico, Ronald
    Orkin, Chloe
    Bernal Morell, Enrique
    Tan, Darrell H. S.
    Katner, Harold
    Singh, Yashna
    Stellbrink, Hans-Juergen
    Belonosova, Elena
    DeMoor, Rebecca
    Griffith, Sandy
    Thiagarajah, Shanker
    Van Solingen-Ristea, Rodica
    Crauwels, Herta
    Ford, Susan L.
    Patel, Parul
    Cutrell, Amy
    Smith, Kimberly Y.
    Vandermeulen, Kati
    Margolis, David A.
    St Clair, Marty
    Spreen, William R.
    Finkenzeller, Teresa
    [J]. INFECTION, 2021, 49 (SUPPL 1) : S7 - S7
  • [48] Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
    Steegen, Kim
    Chandiwana, Nomathemba
    Sokhela, Simiso
    Venter, Willem D. F.
    Hans, Lucia
    [J]. AIDS, 2023, 37 (06) : 1009 - 1011
  • [49] Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials
    Elliot, Emilie R.
    Polli, Joseph W.
    Patel, Parul
    Garside, Louise
    Grove, Richard
    Barnett, Vincent
    Roberts, Jeremy
    Byrapuneni, Sri
    Crauwels, Herta
    Ford, Susan L.
    Van Solingen-Ristea, Rodica
    Birmingham, Eileen
    D'Amico, Ronald
    Baugh, Bryan
    van Wyk, Jean
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2024, 230 (01): : e34 - e42
  • [50] Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman Living With Human Immunodeficiency Virus
    van der Wekken-Pas, Lena
    Weiss, Fabian
    Simon-Zuber, Charlotte
    Sebisch, Rena
    Wiese, Carmen
    van Leeuwen, Elisabeth
    Burger, David
    Colbers, Angela
    [J]. CLINICAL INFECTIOUS DISEASES, 2024,
12345